Efficacy and safety of co-administered cagrilintide–semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial
Elsevier ·
Аннотация у издателя не опубликована — полный текст доступен по ссылке ниже.
Efficacy and safety of co-administered cagrilintide–semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial. // The Lancet Diabetes & Endocrinology. – URL: https://www.sciencedirect.com/science/article/pii/S2213858726002755?dgcid=rss_sd_all
Efficacy and safety of co-administered cagrilintide–semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial. The Lancet Diabetes & Endocrinology. https://www.sciencedirect.com/science/article/pii/S2213858726002755?dgcid=rss_sd_all
“Efficacy and safety of co-administered cagrilintide–semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial.” The Lancet Diabetes & Endocrinology.
@article{article68332,
title = {Efficacy and safety of co-administered cagrilintide–semaglutide (CagriSema) 1·7 mg each and 1·0 mg each in adults with overweight or obesity (REDEFINE 9): a multicentre, randomised, double-blind within-dose-level, placebo-controlled, parallel-group, phase 3b trial},
journal = {The Lancet Diabetes \& Endocrinology},
url = {https://www.sciencedirect.com/science/article/pii/S2213858726002755?dgcid=rss_sd_all}
}